BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

741 related articles for article (PubMed ID: 19212958)

  • 1. IgG glycosylation analysis.
    Huhn C; Selman MH; Ruhaak LR; Deelder AM; Wuhrer M
    Proteomics; 2009 Feb; 9(4):882-913. PubMed ID: 19212958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IgG fc N-glycosylation changes in Lambert-Eaton myasthenic syndrome and myasthenia gravis.
    Selman MH; Niks EH; Titulaer MJ; Verschuuren JJ; Wuhrer M; Deelder AM
    J Proteome Res; 2011 Jan; 10(1):143-52. PubMed ID: 20672848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Site-specific N-glycosylation of chicken serum IgG.
    Suzuki N; Lee YC
    Glycobiology; 2004 Mar; 14(3):275-92. PubMed ID: 14693911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of methods for the analysis of therapeutic immunoglobulin G Fc-glycosylation profiles-Part 2: Mass spectrometric methods.
    Reusch D; Haberger M; Falck D; Peter B; Maier B; Gassner J; Hook M; Wagner K; Bonnington L; Bulau P; Wuhrer M
    MAbs; 2015; 7(4):732-42. PubMed ID: 25996192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans.
    Goetze AM; Liu YD; Zhang Z; Shah B; Lee E; Bondarenko PV; Flynn GC
    Glycobiology; 2011 Jul; 21(7):949-59. PubMed ID: 21421994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of glycosylation sites for a recombinant IgG1 monoclonal antibody and a CTLA4-Ig fusion protein by liquid chromatography-mass spectrometry peptide mapping.
    Bongers J; Devincentis J; Fu J; Huang P; Kirkley DH; Leister K; Liu P; Ludwig R; Rumney K; Tao L; Wu W; Russell RJ
    J Chromatogr A; 2011 Nov; 1218(45):8140-9. PubMed ID: 21978954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of methods for the analysis of therapeutic immunoglobulin G Fc-glycosylation profiles--part 1: separation-based methods.
    Reusch D; Haberger M; Maier B; Maier M; Kloseck R; Zimmermann B; Hook M; Szabo Z; Tep S; Wegstein J; Alt N; Bulau P; Wuhrer M
    MAbs; 2015; 7(1):167-79. PubMed ID: 25524468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contrasting glycosylation profiles between Fab and Fc of a human IgG protein studied by electrospray ionization mass spectrometry.
    Mimura Y; Ashton PR; Takahashi N; Harvey DJ; Jefferis R
    J Immunol Methods; 2007 Sep; 326(1-2):116-26. PubMed ID: 17714731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variations in oligosaccharide-protein interactions in immunoglobulin G determine the site-specific glycosylation profiles and modulate the dynamic motion of the Fc oligosaccharides.
    Wormald MR; Rudd PM; Harvey DJ; Chang SC; Scragg IG; Dwek RA
    Biochemistry; 1997 Feb; 36(6):1370-80. PubMed ID: 9063885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Terminal sugars of Fc glycans influence antibody effector functions of IgGs.
    Raju TS
    Curr Opin Immunol; 2008 Aug; 20(4):471-8. PubMed ID: 18606225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunoglobulin G glycopeptide profiling by matrix-assisted laser desorption ionization Fourier transform ion cyclotron resonance mass spectrometry.
    Selman MH; McDonnell LA; Palmblad M; Ruhaak LR; Deelder AM; Wuhrer M
    Anal Chem; 2010 Feb; 82(3):1073-81. PubMed ID: 20058878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro.
    Hodoniczky J; Zheng YZ; James DC
    Biotechnol Prog; 2005; 21(6):1644-52. PubMed ID: 16321047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycan analysis of monoclonal antibodies secreted in deposition disorders indicates that subsets of plasma cells differentially process IgG glycans.
    Omtvedt LA; Royle L; Husby G; Sletten K; Radcliffe CM; Harvey DJ; Dwek RA; Rudd PM
    Arthritis Rheum; 2006 Nov; 54(11):3433-40. PubMed ID: 17075835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MS-Based Allotype-Specific Analysis of Polyclonal IgG-Fc
    Sénard T; Gargano AFG; Falck D; de Taeye SW; Rispens T; Vidarsson G; Wuhrer M; Somsen GW; Domínguez-Vega E
    Front Immunol; 2020; 11():2049. PubMed ID: 32973813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mass spectrometry and HPLC for carbohydrate analysis.
    Siemiiatkoski J; Lyubarskaya Y
    Dev Biol (Basel); 2005; 122():69-74. PubMed ID: 16375251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of immunoglobulin glycosylation by LC-ESI-MS of glycopeptides and oligosaccharides.
    Stadlmann J; Pabst M; Kolarich D; Kunert R; Altmann F
    Proteomics; 2008 Jul; 8(14):2858-71. PubMed ID: 18655055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure analysis of N-glycoproteins.
    Henning S; Peter-Katalinić J; Pohlentz G
    Methods Mol Biol; 2009; 492():181-200. PubMed ID: 19241033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-throughput work flow for IgG Fc-glycosylation analysis of biotechnological samples.
    Reusch D; Haberger M; Selman MH; Bulau P; Deelder AM; Wuhrer M; Engler N
    Anal Biochem; 2013 Jan; 432(2):82-9. PubMed ID: 23026777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing Fc glycan heterogeneity of therapeutic recombinant monoclonal antibodies using NP-HPLC.
    Raju TS
    Methods Mol Biol; 2013; 988():169-80. PubMed ID: 23475719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fc specific IgG glycosylation profiling by robust nano-reverse phase HPLC-MS using a sheath-flow ESI sprayer interface.
    Selman MH; Derks RJ; Bondt A; Palmblad M; Schoenmaker B; Koeleman CA; van de Geijn FE; Dolhain RJ; Deelder AM; Wuhrer M
    J Proteomics; 2012 Feb; 75(4):1318-29. PubMed ID: 22120122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.